Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2
Explore this issueDecember 2015
Also by this Author
Specifically, the recommendations offer guidance on the use of glucocorticoids (GCs) (e.g., initial dose, strategies for tapering off), the use of disease-modifying anti-rheumatic drugs (DMARDs) and the duration of treatment.
Acknowledging the marked, non-evidence-based variations in the use of these therapies is particularly important because of the high rates of GC-related side effects in people with PMR, according to Eric Matteson, MD, chair of rheumatology at the Mayo Clinic in Rochester, Minn., and the ACR co-principal investigator of the guideline development project.